Document:

exhibit10_2.htm

    EXHIBIT
10.2

    Form
of the Forbearance Agreement dated December 15, 2008

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    FORBEARANCE
AGREEMENT

     

    This
Forbearance Agreement (the “Agreement”) is made
as of December 12, 2008 (the “Forbearance Effective
Date”) by and among Lazy Days’ R.V. Center, Inc., a Florida corporation
(“Issuer”), The
Bank of New York, a New York banking corporation, as indenture trustee (“Trustee”), and the
Noteholder signatory hereto (the “Noteholder”), a holder of the Issuer’s
unsecured 11.75% Senior Notes due May 15, 2012 (the “Notes”).  For
purposes of this Agreement, the Issuer, the Trustee and the Noteholder together
are referred to as the “Parties.”  Capitalized
terms used herein have the meanings assigned in the Indenture unless otherwise
defined herein.

     

    RECITALS

     

    WHEREAS,
as of the date hereof, the Issuer has failed to make the interest payment due on
November 15, 2008 under the Indenture, which is a Default, and if not cured
within thirty days, will become an Event of Default under the Indenture (the
“Interest
Default”);

     

    WHEREAS,
at the Issuer’s request, the Noteholder has agreed to forbear from exercising,
and to instruct the Trustee under the Indenture not to exercise those rights and
remedies available under the Indenture and/or applicable law that have arisen or
may hereafter arise, due to the occurrence and continuance of the Interest
Default on the terms and conditions set forth herein;

     

    NOW
THEREFORE, in consideration of the premises and the respective covenants and
agreements set forth in this Agreement, the Parties, each intending to be
legally bound, agree as follows:

     

    
      	
              1.  

            	
              Forbearance.

            

    

     

    
      	
              (a)  

            	
              Effective
      as of the Forbearance Effective Date, the Noteholder agrees that, until
      the expiration of the Forbearance Period (as defined below), it will
      forbear from exercising, and shall direct the Trustee and any broker or
      other Person that holds the Notes on behalf of the Noteholder, and by
      signature hereto so direct the Trustee pursuant to Article VI of the
      Indenture and such brokers or other Persons, not to exercise, any rights
      and remedies against Issuer that are available under the Indenture and/or
      applicable law solely with respect to Interest Default; provided, however, that,
      except as otherwise expressly provided herein, nothing herein shall
      restrict, impair or otherwise affect the exercise of the Noteholder’s
      rights under this Agreement or the Indenture, and provided further that no
      such forbearance shall constitute a waiver with respect to any Defaults or
      Events of Default under the Indenture or a waiver of any of the rights and
      remedies provided thereunder, under applicable law, at equity or
      otherwise.

            

    

     

    
      	
              (b)  

            	
              As
      used herein, the term “Forbearance
      Period” shall mean the period beginning on the Forbearance
      Effective Date and ending upon the occurrence of a Termination
      Event.  As used herein, “Termination
      Event” shall mean the earlier to occur of (i) December 19, 2008;
      and (ii) the occurrence of any Forbearance Default; provided, however, that
      if, on or before December 19, 2008, the Issuer and Noteholder enter into a
      mutually satisfactory confidentiality agreement and the Issuer delivers to
      the Noteholder (X) a copy of the 13-week cash flow statement of the Issuer
      and (Y) the budget for the 2009 fiscal year of the Issuer, then such date
      set forth in Section 1(b)(i) above shall be extended to January 15,
      2009.  As used herein, the term “Forbearance
      Default” shall mean: (A) the occurrence of any Default or Event of
      Default other than the Interest Default; (B) the failure of the Issuer to
      comply with any material term, condition, covenant or agreement set forth
      in this Agreement; (C) the failure of any representation or warranty made
      by the Issuer under this Agreement to be true and correct in all material
      respects as of the date when made; (D) the commencement by or against the
      Issuer of a case under title 11 of the United States Code, the Companies’
      Creditors Arrangement Act or any other act that seeks relief under any
      comparable bankruptcy or insolvency regime or proceeding; (E) the
      failure of the Issuer to have adequate availability and ability to borrow
      under the Floor Plan Credit Facility to meet its current operating cash
      needs; or (f) the acceleration of the Notes pursuant to Section 6.1 of the
      Indenture.

            

    

     

    
      	
              (c)  

            	
              Upon
      the occurrence of a Termination Event, the agreement of the Noteholder
      hereunder to forbear, and to direct the Trustee and any broker or other
      Person that holds the Notes on behalf of the Noteholder, to forbear, from
      exercising rights and remedies in respect of the Interest Default, shall
      immediately terminate without further act or action by the Noteholder or
      the requirement of any demand, presentment, protest, or notice of any
      kind, all of which Issuer hereby waives.  The Issuer agrees that
      upon occurrence of and at any time after the occurrence of a Termination
      Event, the Noteholder or the Trustee, as applicable, may proceed, subject
      to the terms of the Indenture and/or applicable law, to exercise any or
      all rights and remedies under the Indenture and/or applicable law,
      including, without limitation, the rights and remedies on account of the
      Interest Default and any other Defaults or Events of Default that may then
      exist.  Without limiting the generality of the foregoing, upon
      the occurrence of a Termination Event, if any Default or Event of Default
      (including the Interest Default) exists at such time, the Noteholder or
      the Trustee, as applicable, may, upon such notice or demand as is
      specified by the Indenture or applicable law, and subject to the terms of
      the Indenture and/or applicable law, (x) collect and/or commence any legal
      or other action to collect any or all of the obligations of the Issuer
      under the Indenture; and (y) take any other enforcement action or
      otherwise exercise any or all rights and remedies provided to them under
      the Indenture and/or applicable law, all of which rights and remedies are
      fully reserved.

            

    

     

    
      	
              2.  

            	
              Covenants.
      Notwithstanding any provisions to the contrary contained in this
      Agreement, the Issuer hereby covenants and agrees to observe and comply
      with each of the following covenants and the Issuer agrees and
      acknowledges that failure to comply with any such covenant shall result in
      an immediate Termination Event:

            

    

     

    
      	
              (a)  

            	
              The
      Issuer will perform, observe and comply with each covenant, agreement and
      term contained in this Agreement, the Floor Plan Credit Facility and the
      Indenture, other than the Interest
Default.

            

    

     

    
      	
              (b)  

            	
              The
      Issuer will be prohibited, during the Forbearance Period from making any
      Asset Sales or Affiliated Transactions; incurring any Liens; or making any
      Restricted Payments.

            

    

     

    
      	
              (c)  

            	
              The
      Issuer shall promptly, but in any event within twenty four (24) hours,
      notify the Noteholder in writing of any Forbearance
    Default.

            

    

     

    
      	
              (d)  

            	
              The
      Issuer shall pay within 10 days of receipt (i) the reasonable out of
      pocket expenses of the Noteholder (which shall not include fees and
      expenses of counsel except as provided in (ii) below) and (ii) fees and
      expenses of the informal group of unaffiliated holders of the Notes (the
      “Noteholder
      Group”) and its counsel pursuant to the terms of the Engagement
      Letter between the Issuer and Akin Gump Strauss Hauer & Feld LLP dated
      as of December 3, 2008.

            

    

     

    
      	
              (e)  

            	
              The
      Issuer shall negotiate in good faith with the Noteholder Group regarding a
      potential restructuring
transaction.

            

    

     

    
      	
              3.  

            	
              Effectiveness.  This
      Agreement shall be effective as to the Noteholder and the Issuer in
      accordance with Section 3 hereof regardless of whether the Trustee
      executes this Agreement.  This Agreement shall be effective as
      to the Trustee when the Trustee becomes a signatory
  hereto.

            

    

     

    
      	
              4.  

            	
              Representations
      and Warranties.

            

    

     

    
      	
              (a)  

            	
              The
      Issuer represents and warrants
that:

            

    

     

    
      	
              (i)  

            	
              Except
      for the Interest Default, no other Default or Event of Default has
      occurred and is continuing.

            

    

     

    
      	
              (ii)  

            	
              The
      Issuer is duly organized, validly existing and in good standing under the
      laws of the jurisdiction of its organization, and has the full power and
      authority to execute, deliver and perform this
  Agreement.

            

    

     

    
      	
              (iii)  

            	
              The
      execution, delivery and performance by the Issuer of this Agreement (A)
      have been duly authorized by all requisite action on the part of the
      Issuer, (B) do not and will not violate the certificate of
      incorporation or bylaws of the Issuer, or any material agreement of the
      Issuer, or any order, judgment or decree of any court, governmental agency
      or arbitrator by which the Issuer or any of its properties is bound, and
      (C) does not and will not require any filing (other than any disclosure
      filing) or registration with, consent, or authorization or approval of, or
      notice to, or other action with or by, any governmental agency or other
      Person.

            

    

     

    
      	
              (iv)  

            	
              This
      Agreement constitutes the legal, valid and binding obligation of the
      Issuer, enforceable against the Issuer in accordance with its terms,
      except as enforcement may be limited by equitable principles or by
      bankruptcy, insolvency, reorganization, moratorium, or similar laws
      relating to or limiting creditors’ rights
  generally.

            

    

     

    
      	
              (b)  

            	
              The
      Noteholder represents as follows: As of the date hereof, the Noteholder
      either (A) is the sole legal and beneficial owner of the principal
      amount of Notes set forth opposite its name on the signature
      pages hereto, or (B) has the investment or voting discretion
      with respect to such Notes and has the power and authority to bind the
      beneficial owner(s) of such Notes to the terms of this
      Agreement.

            

    

     

    
      	
              5.  

            	
              Disclosure.  Each
      Party hereto agrees that it will permit public disclosure, including in a
      press release, of the contents of this Agreement, but not including
      information with respect to the Noteholder’s amount of ownership of Notes
      or the identity of the Noteholder.  Notwithstanding anything in
      this Agreement to the contrary, Issuer shall not, and the Issuer hereby
      agrees that it will not, share the identity of the Noteholder or the
      amount of Notes held by the Noteholder with any person or entity and that
      it will keep such information
confidential.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              6.  

            	
              Complete Integration;
      Amendments.  This Agreement along with the Indenture
      constitutes the full and final agreement between the Parties with respect
      to the subject matter hereof, and it may not be modified or amended except
      by a written instrument, signed by each of the Parties, expressing such
      amendment or modification.

            

    

     

    
      	
              7.  

            	
              No Other Amendments;
      Reservation of Rights, No Waiver.  Other than as otherwise
      expressly provided herein, this Agreement shall not be deemed to operate
      as an amendment or waiver of, or to prejudice, any right, power, privilege
      or remedy of the Noteholder or the Trustee, as applicable, under the
      Indenture or applicable law, nor shall the entering into this Agreement
      preclude the Noteholder from refusing to enter into any further amendments
      or forbearances with respect to the Indenture.  Other than as
      expressly provided herein, this Agreement shall not constitute a
      forbearance with respect to (i) any failure by the Issuer to comply
      with any covenant or other provision in the Indentures or (ii) the
      occurrence or continuance of any present or future Default or Event of
      Default.

            

    

     

    
      	
              8.  

            	
              Counterparts/Facsimile
      Transmission.  This Agreement may be signed in counterparts,
      each of which, when taken together, shall be deemed an original. Execution
      of this Agreement is effective if a signature is delivered by facsimile
      transmission or electronic (e.g., “pdf”)
  transmission.

            

    

     

    
      	
              9.  

            	
              Successors and
      Assigns.  This Agreement shall be binding upon and inure to
      the benefit of the Parties hereto and each of their respective successors,
      assigns, heirs and personal
representatives.

            

    

     

    
      	
              10.  

            	
              Authority.  Any
      person signing this Agreement in a representative capacity
      (i) represents and warrants that he/she is authorized to sign this
      Agreement on behalf of the Party he/she represents and that his/her
      signature upon this Agreement will bind the represented Party to the terms
      of this Agreement, and (ii) acknowledges that the other Party to this
      Agreement has relied upon such representation and
  warranty.

            

    

     

    
      	
              11.  

            	
              Governing Law. 
      This Agreement shall be governed by and construed in accordance with the
      laws of the State of New York, without regard to its choice of law
      provisions.

            

    

     

    
      	
              12.  

            	
              Remedies.  Nothing
      contained in this Agreement shall be deemed a waiver by any non-breaching
      Party hereto of any other remedies available at law to redress any other
      Party’s breach of this Agreement.  Each of the rights and powers
      provided pursuant to this Agreement shall be cumulative and in addition to
      and not in derogation of the rights and powers otherwise available under
      applicable law to the Parties pursuant to Article VI of the
      Indenture.

            

    

     

    
      	
              13.  

            	
              Direction to
      Trustee.  The Noteholder’s agreement to forbear as provided
      herein shall constitute a direction from the Noteholder to the Trustee to
      similarly forbear during the Forbearance
Period.

            

    

     

    
      	
              14.  

            	
              Acquisition of Additional
      Notes.  This Agreement shall in no way be construed to
      preclude the Noteholder from acquiring additional Notes to the extent
      permitted by applicable law and to the extent not subject to any other
      contractual restrictions.  However, the Noteholder shall,
      automatically and without further action, become subject to this Agreement
      with respect to any Notes so
acquired.

            

    

     

    
      	
              15.  

            	
              Limitation on Transfers of
      Notes.  The Noteholder hereby agrees not to sell, assign,
      pledge, hypothecate or otherwise transfer, during the Forbearance Period,
      any Notes (or any rights in respect thereof, including the right to vote)
      that are subject to this Agreement and held by the Noteholder as of the
      execution date of this Agreement except to a party who, contemporaneously
      with any such sale, assignment, pledge, hypothecation, or transfer, agrees
      to be fully bound as a signatory hereunder by executing and delivering to
      the Issuer a joinder to this Agreement.  If the Noteholder takes any
      action in violation of the preceding sentence, the Noteholder shall notify
      the Issuer within one (1) Business Day
    thereafter. 

            

    

     

    
      	
              16.  

            	
              No Limitation on Business
      Activities.  Notwithstanding the foregoing or any other
      term contained herein, Issuer acknowledges and agrees that this letter
      agreement shall not in any way limit the lawful activities of Noteholder
      in businesses distinct from the business of the group which holds the
      Notes.

            

    

     

    

      
        
           

        

        
           

          
            

          

        

        
           

        

      

    IN
WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be duly
executed and delivered as of the date first above written.

     

    

     

    Lazy Days’ R.V. Center,
Inc.

     

    By:_____________________

     

    Name:

     

    Title:

     

    

     

    

     

    The Bank of New York

     

    By:_____________________

     

    Name:

     

    Title:

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    NOTEHOLDER

     

    By:

     

    Name:

     

    Title:

     

    Address:

     

    _____________________

     

    _____________________

     

    _____________________

     

    Attn:

     

    Tel:

     

    Fax:

     

    Email:

     

    Principal Amount of Senior Notes
Held:

     

    $_____________________________

     

    Date:EX-10.1

Exhibit 10.1

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [  *  ].
A complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

MANUFACTURE AND SUPPLY AGREEMENT

This Agreement made as of this 8th day of October 2008, by and between Siemens AG
Healthcare Sector, Components & Vacuum Technology, having a business address at Henkestrasse 127,
91052 Erlangen, Germany (“Seller”) and TomoTherapy Incorporated, having a business address at 1240
Deming Way, Madison, WI 53717, USA (“Buyer”).

WITNESSETH:

WHEREAS, Seller has experience and expertise in the manufacturing and/or supporting the products
(herein collectively referred to as “Products”) listed in Exhibit A for a period specified in this
Agreement; and

WHEREAS, Buyer wishes to have Seller use its expertise to continue manufacturing and/or supporting
the products (herein collectively referred to as “Products”) listed in Exhibit A for the period
specified in this Agreement; and

NOW, THEREFORE, for good and valuable consideration, the adequacy of which is hereby acknowledged,
the Seller and Buyer do hereby agree to covenant and promise the following:

1. SCOPE

Commencing on the effective date of this Agreement Buyer shall provide Seller with a twelve
(12) month rolling forecast. The initial forecast will be accompanied by a firm purchase
order for the first six (6) months and a projection of orders for the next six (6) months,
subject to the lead time stated in Exhibit B. In accordance with this Agreement, Buyer shall
update the twelve (12) month rolling forecast on a quarterly basis and issue purchase orders
subject to the lead time in Exhibit B. Seller will provide the personnel, technical
services and facilities necessary in order to manufacture the Products for Buyer (as defined
in Exhibit A which is hereby incorporated by reference).

Neither party shall be deemed to be in default of this Agreement if prevented from
performing any obligation hereunder for any reason beyond its reasonable control including,
without limitation, governmental laws and regulations, terrorists acts, Acts of God or the
public, calamities, floods, diseases and storms.

This Agreement shall serve as a full replacement to the Manufacture and Supply Agreement
made as of the 14th day of November 2003 by and between Siemens Medical
Solutions, USA, Inc. Oncology Care Systems, Concord, CA 94520 and TomoTherapy, Inc. Madison,
WI 53717 for purchases made on or after the date of this Agreement. No other reference to
this preceding Agreement shall be made.

2. PURCHASE ORDER PLACEMENT

a) Buyer shall update the twelve (12) month rolling forecast on a quarterly basis. Buyer
will provide Seller an annual blanket purchase order (i.e. SAP Quantity Contract) for the
Accelerator Assembly (part number [ * ]) to set the employed discount break-point for the
coming contract year. . Buyer will issue Purchase Orders subject to the lead time stated in
Exhibit B. Buyer may delay delivery on a purchase order by as much as 30 days, provided
such delay notice is delivered to Seller not less than 60 days prior to the original
scheduled Delivery Date.

As a condition of this Agreement, Buyer agrees to take delivery of a minimum of [ * ]
Accelerator Assemblies per year, part number [ * ], commencing with the effective date of
this Agreement. Said minimum shall be binding upon the parties and any their successors or
assign. Notwithstanding the above, the Buyer will provide a rolling purchasing forecast for
Seller’s planning purpose only, every quarter in each Fiscal Year. The quantities indicated
for the immediate quarter shall be considered binding for purchase and delivery by Buyer and
Seller. The Buyer can take delivery of less than [ * ] Accelerator Assemblies (part number
[ * [) in a given contract year at the price of [ * ]% off of the Exhibit B Base Price.

Seller shall formally acknowledge Buyer’s purchase orders by fax or e-mail and provide a
confirmation of delivery dates. All products shall be delivered in full on or up to 5 days
before the scheduled due date.

Any “Terms and/or Conditions” printed upon a purchase order document from Buyer shall not
apply.

The effective discount break-point applicable for the Accelerator Assembly, part number [ *
], will be based upon the annual deliveries executed and reviewed within the following month
of the successive period. Warranty replacement deliveries are not to be included. Deviation
from the employed discount break-point and effective discount break-point are to be
corrected and subsequent a credit or an invoice will be issued by Seller to balance Buyer’s
account.

b) If “Buyer” requests a repair of a product supplied by “Seller”, Buyer will enquire in
writing: i) if repair of a Product is possible, ii) if repair is economically feasible –
evaluated through quotation from Seller, iii) and if i) or ii) are positive, a pertinent
Purchase Order will be issued by Buyer for the repair of said Product, which is to be
acknowledged in writing by Seller within five (5) days from the date of receipt. Seller
will provide repair of out-of warranty Accelerator Assemblies (part number [ * ]) at a price
not to exceed $[ * ] . Final price and warranty will be set in an addendum to the contract
once the repairing and testing of ten (10) units are complete.

3. PACKAGING

Packaging of the Products shall be in a manner adequate to ensure undamaged

arrival at Buyer’s business address, when transported by airplane, truck or railroad. All
deliveries shall be accompanied by a shipping list. Seller will endeavor to develop local
packaging (wooden crate and blue box) based on specifications provided by Buyer. When and
if Seller develops a local source, Buyer will pay the cost of such locally- provided
packaging.

4. DEVELOPMENT PROJECTS

Each party will actively seek to identify opportunities to improve quality and reliability,
as well as reduce costs, for the Products. The parties agree to work cooperatively to
implement such improvements. The parties agree that, should they decide to work together on
new product development projects, such new product development efforts will be covered under
a new agreement.

5. TERM

This Agreement shall remain in full force and effect until [ * ]. This Agreement shall be
automatically renewed for additional renewal terms of twelve (12) months each, unless either
party gives the other party at least eleven (11) months prior written notice of election to
terminate this Agreement effective at the end of the then current term. In the event that
the Seller elects to terminate this Agreement in accordance with the above terms, the Buyer
shall have the right to place a “last time” Purchase Order no later than 90 days prior to
the termination of this Agreement to provide Buyer with sufficient quantity to meet the
Buyer’s expected product needs for the one (1) year period immediately following termination
of this Agreement. The parties will negotiate in good faith the delivery schedule for each
product covered by such ”last time” Purchase Order, but it is presumed that Buyer will take
delivery of those products equally over the first nine months after termination of this
Agreement.

6. PRICING

The pricing for Products shall be U.S. Dollars (USD) in accordance with Exhibit B and shall
be valid until [ * ].

7. DELIVERY, PAYMENT TERMS

Delivery is FCA Frankfurt Airport (INCO Terms 2000). Seller shall specify the carrier.
Costs incurred for freight, customs, duties and other similar charges shall be paid by
Seller every six months upon receipt of a written statement of such charges from Buyer.

Payment shall be effected no later then 30 days from date of invoice and registered to the
account given on the invoice.

Title for Products passes to Buyer at Delivery as stated above. However, until payment in
full for each delivery of Products is received by Seller, and if payment is not made in a
timely manner, Seller may demand return of and repossess Products.

8. RETURNS/DISPOSAL

If at the end of the life cycle of the Products, Buyer is legally obliged to take back
and/or dispose of the Products, Seller shall accept such Products if and to the extent
Seller is also legally bound to take the said Products back and dispose of them. The costs
for return and disposal of the Products shall be borne by Buyer.

9. WARRANTY

All Products provided under this Agreement shall be in accordance with Seller’s
specifications. Seller warrants for all Products listed in Exhibit B maintaining an
appropriate level of ISO certification and compliance to ISO 13485. Seller further warrants
that all Products sold to Buyer under this Agreement comply with the requirements of the
U.S. Food and Drug Administration (“FDA”) and the FDA’s Good Manufacturing Practices (“GMP”)
with respect to the manufacture, package, assembly and testing for the Products and that all
Products provided under this Agreement shall be in accordance with the Seller’s
specifications.

Except for part number [ * ], which is warranted for eighteen months from the Date of
Delivery, or twelve months from date of installation at a customer site, whichever occurs
first. Seller warrants that all other Products will be free from defects in materials and
workmanship for a period of six (6) months from the Date of Delivery. The time period for
all warranties shall be suspended during any period in which Seller has returned Products
and is evaluating or repairing or reworking them as set forth in subsequent paragraphs of
this Section 8. When Buyer has developed sufficient data, Buyer will propose and Seller
will consider warranties for one or more Products based on beam-on time rather than a
time-based warranty.

Buyer may return to Seller any Product still under warranty that it believes is defective,
and shall take a credit for such Product within ninety days of return. The returned
Product shall be accompanied by an appropriate description of defect. Seller shall perform
an inspection and test of returned Accelerator Assembly Product (part number [ * ]) to
confirm that there is a defect during warranty period. Seller — at its option — will repair
or replace defective Product within 90 days of return. Though not obligated to do so,
Seller may at its sole unilateral option elect to conduct inspection and test on any
Products other than the Accelerator Assembly Product under this Agreement.

Buyer’s remedy is contingent on (1) prompt written notification of the defect; (2) the cause
of the defect not being the result of misuse, accident, neglect, alteration, improper
testing, improper storage, improper installation or negligence on the part of the Buyer; and
(3) return of the Products to Seller’s manufacturing location with shipment and in-transit
loss or damage at the risk an expense of the Buyer. Such repair, replacement or credit shall
constitute fulfillment of all liability of Buyer to Seller whether based in contract, tort,
and indemnity or otherwise.

If an Accelerator Assembly Product has been returned to Seller under warranty and Seller is
unable to confirm a failure for it after Buyer has had a full opportunity to verify the
cause of the failure, explain the same to Seller, and Seller has conducted tests necessary
to confirm the failure, Seller shall invoice Buyer at the manufacturing rate of $[ * ]
/hour, at an amount not to exceed the equivalent of 40 labor hours ($[ * ]). Seller must
obtain a purchase order from the Buyer for testing beyond the amount of $ [ * ].

EXCEPT AS EXPRESSLY SET FORTH IN THE PRECEDING SENTENCES AND/OR IN SPECIFICATIONS; SELLER
MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION,
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE
PRODUCTS.

10. LIMITATION OF LIABILITY; BUYER’S REMEDIES

10.1 EXCLUSIVE REMEDY

Claims on the part either party other than those expressly mentioned in this Agreement
especially claims for damages, reduction of price or withdrawals from this Agreement,
regardless of their legal grounds, shall be excluded.

10.2 LIMITATION OF LIABILITY

However, claims on the either party shall be limited to a maximum liability to the other
party relating to claims for property damage of $ [ * ] for all such events, performed
under this Agreement.

Neither party shall under no circumstances be liable for: a) indirect, consequential,
incidental, punitive or special damages; b) loss of production, interruption of operations,
loss of profit or revenue, payment of interest and other financing expenses, loss of
information and data; c) loss of or damage to property other than the Products.

10.3 MANDATORY LAW

This disclaimer of liability shall not apply in cases involving intent or gross negligence,
or where sections of the Federal Law of Switzerland regarding Product Liability (PrHG) are
mandatory, or where liability is mandatory as in cases of damage to privately used
property.

11. TERMINATION

If either party materially breaches its obligations in this Agreement, the other party may
terminate this Agreement by giving not less than 30 days notice to the other party.
Termination will not occur if the defaulting party, within such thirty (30) day period,
remedies such breach to the reasonable satisfaction of the non-defaulting party.

This Agreement may be terminated immediately by either party without the requirement of
prior notice, if the other party suspends operations, files or suffers to be filed against
it a petition for bankruptcy, or the like, executes an assignment for the benefit of
creditors, or is adjudicated as bankrupt. This Agreement may also be terminated if the
percent of Accelerator Assembly Products that fail within the one-year warranty period due
to manufacturing and/or material defects exceeds [ * ] percent [ * ].

Sections 9, 10, 11, 12, 13, 14 and 15 shall survive termination or cancellation of this
Agreement.

	12.	 	EXPORT

Each party agrees that it will not knowingly (i) export or re-export, directly or
indirectly, any technical data (as defined by the U.S. Export Administration Regulations),
including software received from the other under this Agreement, (ii) disclose such
technical data for use in, or (iii) export or re-export, directly or indirectly, any direct
product of such technical data, including software, to any destination to which such export
or re-export is restricted or prohibited by U.S. or non-U.S. law without obtaining prior
authorization from U.S. Department of State and other competent authorities to the extent
required by those laws.

Further, both party’s obligation to fulfill this agreement is subject to the proviso that
the fulfillment is not prevented by any impediments arising out of national and
international foreign trade and customs requirements or any embargos or other sanctions.

	13.	 	INDEMNIFICATION, OVERALL LIMITATION OF LIABILITY

	 	a)	 	Bodily Injury, Disability, Death or Property Damage

Each party agrees to indemnify the other, its officers, agents, servants and employees
against claims, damages demands, suits actions judgments, liabilities, defaults, or
costs and expenses, including attorney’s fees, arising from claims made against or
liability imposed upon the other, by a court of competent jurisdiction as the results of
claims alleging personal injury, disability, death or property damage or any form or
type or wrongdoing or loss arising from the indemnifying party’s failure to perform its
respective obligations hereunder. Such indemnity obligations shall only apply if the
indemnified party is notified promptly in writing of such claim, suit or legal
proceedings, and given full and complete authority to defend the same, and given such
information as the indemnifying party may have regarding the same as may be reasonably
required for the defense of the same.

In Buyer’s case, such indemnity obligations shall also apply to claims arising out of or
in connection with Buyer’s assembly and resale of the Products, including without
limitation, Buyer’s burden of customer training, service and support, its
representations made in the course of reselling or distribution of the products, and its
distribution of related materials and literature.

	 	b)	 	Intellectual Property Infringement

The Seller agrees, at its cost and expense, to defend any claim, suit or legal
proceeding asserted or brought against the Buyer or the Buyer’s customers, that any
Products, or the use thereof, infringes any patent, copyright or other intellectual
property right of a third party, provided the Seller is notified promptly in writing of
such claim, suit or legal proceeding, and given full and complete authority to defend
the same, and given such information as the Buyer may have regarding the same as may be
reasonably required for the defense of the same. The Seller shall pay all damages,
awards and costs, awarded. The Seller shall not be responsible for any settlement
negotiated and agreed to by the Buyer or any other party without the consent of the
Seller. The Seller shall have the right, at its own election and at its own expense, to
either (a) procure for the Buyer the right to continue to distribute and use such
Products or part of component, thereof or (b) modify the same so that it becomes
non-infringing provided that the functionality, level of performance, features and
quality thereof are not affected and Seller shall effectuate these remedies as soon as
possible after notice of infringement. In addition, Seller may repurchase such Product
(the repurchase price to be based on the original price paid by the Buyer less
depreciation on a straight line basis over five (5) years, commencing with the date of
installation and start up of such Product). The Buyer shall have the right, at its own
election, to return any such affected Product to the Seller for refund of the purchase
price as set forth above, and to cancel any outstanding Orders or further deliveries of
the Product, without any liability to the Seller with respect thereto.

Notwithstanding the foregoing, the Seller shall not have any liability to the Buyer
under the provision of Section 12 (b), that (i) is based upon the interconnection and/or
the use of a Product, or part thereof, in combination with products or other devices
outside the scope of this Agreement without the prior written consent of the Seller,
which are not made by the Seller whether or not supplied hereunder, or (ii) for use in
any manner for which the Product, or part thereof, was not designed or created. Also,
the Buyer shall hold the Seller harmless against any expense, judgment or loss for
infringement of any patent or copyright that results from the Seller’s compliance with
the incorporation of designs specifications furnished by the Buyer.

The foregoing states the entire liability of the parties with respect to infringement of
intellectual property right by the Products or any part thereof.

	 	c)	 	Liability Insurance

Buyer covenants that it will maintain liability insurance adequate to fulfill the
indemnification obligation hereunder in each such 12-month period commencing on October
1st of each year. Seller is self-insured and covenants that it has sufficient
capital to meet all obligations hereunder.

Notwithstanding anything to the contrary in this Agreement, each party’s liability to
the other for liability other than intellectual property infringement, including
obligations to indemnify, hold harmless, etc., shall be limited to a maximum amount of
$[ * ] in the aggregate in any given year.

14. CONFIDENTIALITY

During the term of this Agreement and for five (5) years after the latter of either the
termination of this Agreement or the Enumerative List and Specification of Products
(Exhibit A) under this Agreement, each party shall use the same efforts is uses to protect
its own confidential information (but in any event, no less than reasonable efforts to
prevent it disclosure) to hold in strict confidence and to require its personnel to hold in
strict confidence and not disclose to (1) any employee, director, or agent that does not
need to know such information for the purpose of carrying out this Agreement or (2) any
third party without the prior written consent of the disclosing party, and not use in any
manner except for purposes of carrying out this Agreement and otherwise in accordance with
the terms of this Agreement, any confidential information of the other party in its
possession.

Such confidential information specifically may include, without limitation, all engineering
drawings, specifications and other technical documentation, any proposed design and
specifications for future products and products in development, marketing plans, costs and
pricing information, all third party information required to be maintained in confidence,
and any other information that the disclosing party has marked as confidential.
Confidential Information shall include any copies or abstracts made thereof as well as any
apparatus, modules, samples, prototypes or parts thereof.

Promptly following termination of this Agreement or upon the request by or for the
disclosing party, the receiving party shall surrender to the disclosing party or destroy
all materials remaining in its possession containing any such confidential information
including all copies, extracts, or transcriptions, regardless of media. This shall not
apply to copies of electronically exchanged Confidential Information made as a matter of
routine information technology backup and to Confidential Information or copies thereof
which must be stored by the receiving party or its advisers according to provisions of
mandatory law, provided that such Confidential Information or copies thereof shall be
subject to the confidentiality obligation according to the terms and conditions set forth
herein.

For purposes of this Agreement and the Products and Statement of Work, information shall
not be deemed confidential:

	 	a.	 	if such information is generally available from public sources other than as a
result of the breach of this Agreement

	 	b.	 	if such information is received from a third party not under any obligation to
keep such information confidential

	 	c.	 	if the recipient can demonstrate that such information was independently
developed by the recipient without use of any confidential information of the other
party or its Affiliates; and

	 	d.	 	if such information is marketing material such as catalogs or leaflets
distributed to third parties as part of sales and promotions.

Neither party shall be liable to the other for a breach of these confidentiality obligations
to the extent it is required by law or any governmental body to disclose any confidential
information of the other party; provided, however, unless otherwise required by such
governmental body or such law, the party providing such information to such governmental
body or disclosing the same pursuant to requirement of law shall first notify the other
party so as to enable the other party opportunity to take steps it deems appropriate to
protect its confidential or proprietary information.

15. Arbitration, Substantive Law

All disputes arising out of or in connection with the present Agreement including any
question regarding its existence, validity or termination, which cannot be settled in due
time by the parties, shall be finally settled under the Rules of Conciliation and
Arbitration of the International Chamber of Commerce, Paris (“Rules”) by three arbitrators
appointed in accordance with the said Rules.

Each party shall nominate one arbitrator for confirmation by the competent authority under
the applicable Rules (Appointing Authority). Both arbitrators shall agree on the third
arbitrator within 30 days. Should the two arbitrators fail, within the above time limit, to
reach agreement on the third arbitrator, he shall be appointed by the Appointing Authority.
If there are two or more defendants, any nomination of an arbitrator by or on behalf of such
defendants must be by joint agreement between them. If such defendants fail, within the time
limit fixed by the Appointing Authority, to agree on such joint nomination, the proceedings
against each of them must be separated.

The seat of arbitration shall be Zurich, Switzerland. The procedural law of this place shall
apply where the Rules are silent.

The language to be used in the arbitration proceeding shall be English.

Any disputes shall be settled in accordance with the provisions of this Agreement and any
other agreements regarding its performance, otherwise in accordance

with the substantive law in force in Switzerland without reference to any other law and
without regard to its conflicts of law principles.

The United Nations Convention on Contracts for the International Sale of Goods of April 11,
1980 shall be excluded.

16. NOTICES

All contractual notices from one party to the other under this Agreement shall be in writing
and either personally delivered or sent via certified mail, (E-mail or other electronic
media are not acceptable), postage prepaid and return receipt requested, to:

	 	 	 
	Buyer:

 

	 	TomoTherapy Inc.

1240 Deming Way

Madison WI 53717, USA

attention: Robert Zahn

 
	Seller: 

	 	Siemens AG Healthcare Sector

Components & Vacuum Technology

Henkestrasse 127

91052 Erlangen, Germany

attention: Johann Schwarzenecker

or to such other person or places as either party may designate from time to time by
notice hereunder. Such notices shall be deemed effective upon personal delivery or deposit
in the mails in accordance herewith. A notice or a document required to be “in writing” or
“in written form”, such notice or document shall be duly signed by the sender.

17. Assignment

	 	 	 	Assignment of this Agreement may be made only upon the prior written consent by the other
party; provided, however, that Seller may assign this Agreement to any parent,
affiliate or subsidiary corporation upon notice by Buyer. Any attempted assignment or
transfer of any of the rights, duties or obligations to this Agreement without the
prior written consent of the other party shall be void. If consent is given, this
Agreement shall be binding upon and inure to the benefit of the assigns.

18. Conflicts with Other Terms and Conditions

This Agreement contains all of the terms and conditions as they relate to the relationship
between Buyer and Seller. Any terms and conditions, other than price, quantity, and shipping
instructions, which may be specified on Buyer’s purchase order, are null and void unless
expressly agreed upon in writing by Seller’s representative responsible for contract
administration.

1

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above.

	 	 	 	 	 
	 

	 	TomoTherapy Incorporated

1240 Deming Way

Madison, WI 53717

USA

 
	 	                               

	 

	 	By: Fred Robertson

Title: Chief Executive Officer

Signature: /s/ Fred Robertson

 
	 	

	 

	 	Siemens AG Healthcare Sector

Components & Vacuum Technology

Henkestrasse 127

91052 Erlangen

Germany

 
	 	

	 

	 	By: Manfred Apel

Title: General Manager

Signature: /s/ Manfred Apel

 
	 	

	 

	 	By: Johann Schwarzenecker

Title: Vice President Marketing, Sales

Signature: /s/ Johann Schwarzenecker

 
	 	

	 

	 	Date: 11.12.2008
	 	

	
 
	 	Agreed with respect to clause 1, paragraph 3:
	 	

	
 
	 	Siemens Medical Solutions U.S.A.

Oncology Care systems

Concord, CA 94520
	 	

	 

	 	By: Martin Wentzlik

Title: VP Finance & Administration

Signature: /s/ Martin Wentzlik

 
	 	

	 

	 	Date: 1/13/09

 
	 	

2

EXHIBIT A

Enumerative List and Specification of Products

Product Documents:

In addition to “[ * ] Design Specification [ * ], which is the governing document for the round
waveguides (P/N: [ * ]); the following Seller’s Product documents are hereby incorporated by
reference.

Seller shall formally notify Buyer of any Product changes that affect form, fit or function.

The following Seller’s Product documents are hereby incorporated by reference. Buyer acknowledges
receipt of such Product documents.

	 	 	 
	Part Number	 	Description
	[ * ]

	 	Accelerator Assy, Top Tomo
	[ * ]

	 	AFC ASSY, G39
	[ * ]

	 	Attenuator, RF 20DB N 250 watts
	[ * ]

	 	Circulator Flange Probe Assembly, G8
	[ * ]

	 	Circulator U Elbow
	[ * ]

	 	Circulator Water Load Assembly
	[ * ]

	 	Dose Chamber Assy
	[ * ]

	 	Drive Assy-Magn Tuner-M5
	[ * ]

	 	HV Standoffs
	[ * ]

	 	Injector Assy, Elect-G45
	[ * ]

	 	O-Ring, Buna-N 3.975-ID M4152TR
	[ * ]

	 	PCB ASSY, AFC Control, G39
	[ * ]

	 	PCB ASSY, AFC Pre-Amp, G39
	[ * ]

	 	PCB ASSY, INJ HV PULSER
	[ * ]

	 	PCB ASSY, LV CONTROL I&S
	[ * ]

	 	PWR SPL Assy, ION PMP, 12V-A20
	[ * ]

	 	RF Circulator Assy, KD2-G36
	[ * ]

	 	RF Diode Detector
	[ * ]

	 	RF Diode, Matched Pair
	[ * ]

	 	RF Line Stretcher, ‘N’
	[ * ]

	 	RF, Detector Mount “N”
	[ * ]

	 	Target Assy, Mono 6MV / Primart
	[ * ]

	 	Target, Spinning Tungsten

11/12.08 FR JS

Date / Buyer / Seller

3

EXHIBIT B

PRODUCT PRICING

	 	 	 	 	 	 	 
	Part	 	 	 	Base	 	Lead Times
	Number	 	Description	 	Price(USD)	 	(Days)
	[ * ]

	 	PWR SPL Assy, ION PMP, 12V-A20
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Drive Assy-Magn. Tuner-M5
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Dose Chamber Assy
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Injector Assy, Elect-G45
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Target Assy, Mono 6MV / Primart
	 	[ * ]
	 	[ * ]
	[ * ]

	 	RF Circulator Assy, KD2-G36
	 	[ * ]
	 	[ * ]
	[ * ]

	 	RF Diode Detector
	 	[ * ]
	 	[ * ]
	[ * ]

	 	RF Diode, Matched Pair
	 	[ * ]
	 	[ * ]
	[ * ]

	 	RF, Detector Mount “N”
	 	[ * ]
	 	[ * ]
	[ * ]

	 	RF, Line Stretcher, “N”
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Attenuator, RF 20DB N 250 watts
	 	[ * ]
	 	[ * ]
	[ * ]

	 	O-Ring, Buna-N 3.975-ID M4152TR
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Accelerator Assy, Top Tomo
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Target, Spinning Tungsten
	 	[ * ]
	 	[ * ]
	[ * ]

	 	HV Standoffs
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Circulator Flange Probe Assy. G8
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Circulator U Elbow
	 	[ * ]
	 	[ * ]
	[ * ]

	 	Circulator Water Load Assy.
	 	[ * ]
	 	[ * ]
	[ * ]

	 	AFC ASSY, G39
	 	[ * ]
	 	[ * ]
	[ * ]

	 	PCB Assy. AFC Control, G39
	 	[ * ]
	 	[ * ]
	[ * ]

	 	PCB Assy. AFC Pre-Amp. G39
	 	[ * ]
	 	[ * ]
	[ * ]

	 	PCB Assy. Inj. HV Pulser
	 	[ * ]
	 	[ * ]
	[ * ]

	 	PCB Assy. LV Control I&S
	 	[ * ]
	 	[ * ]

Buyer shall receive a [ * ] percent discount off the above listed Base Prices.

Buyer shall be entitled to the following break-point discount on part number [ * ] when Buyer
provides Seller an annual blanket purchase order (i.e. SAP Quantity Contract) for the Accelerator
Assembly (part number [ * ]) to set the employed discount break-point for the coming contract year.
A discount break-point review –and if applicable an adjustment shall be made on a quarterly basis.
Each twelve (12) month period shall run from October 1st of each year through September
30th of the following year.

The below stated discount break-points apply to quantities stated on the aforementioned twelve (12)
month Buyer’s purchase order, executed by Seller and delivered to Buyer. Excluded from the
quantity-count are acknowledged warranty replacement deliveries and repaired waveguides by Seller
during the same period.

4

5

	 	 	 
	Discount

	 	Quantity of P/N [ * ]
	[ * ]%

	 	If yearly PO quantity is less than [ * ] units
	[ * ]%

	 	If yearly PO quantity is betweeen [ * ] and [ * ] units
	[ * ]%

	 	If yearly PO quantity is between [ * ] and [ * ] units
	[ * ]%

	 	If yearly PO quantity is between [ * ] and [ * ] units
	[ * ]%

	 	If yearly PO quantity is between [ * ] and [ * ] units
	[ * ]%

	 	If yearly PO quantity is between [ * ] and [ * ] units
	[ * ]%

	 	If yearly PO quantity is between [ * ] and more units

Further additional, cumulative discount is to be applied to the applicable discount level above for
P/N [ * ], for the successive periods listed:

	 	 	 
	[ * ]%

[ * ]%

[ * ]%

[ * ]%

	 	from [ * ] to [ * ]

from [ * ] to [ * ]

from [ * ] to [ * ]

from [ * ] to [ * ]

Sample calculation for discount application:

Assumed are [ * ] pcs. waveguides purchased annually, at [ * ]% discount during the period of
January 2011, therefore the applied formula equals:

[ * ]

11/12.08 FR JS

Date / Buyer / Seller

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]